Panacea Biotec Limited’s revenue in Q3FY23 fell 26% to ₹ 11,520 lakhs. Consolidated Profit After Tax came at ₹ 1,937 lakhs in Q3FY23. In this quarter’s results, the reports suggested that the firm has reported decreased revenues and the reason for the increased profitability is the income recieved from Exceptional Items.
Panacea Biotec Q3FY23; 26% Fall in Revenue
Tags: Pharmaceutical
Related Post
- Sula Vineyards Limited posts lower Q3 FY26 profit as tactical destocking hits margins; wine tourism revenue rises
Sula Vineyards Limited (NSE: SULA, BSE: 543711) reported lower profit for the quarter ended Dec.…
-
Filatex India Limited posts stable Q3 FY26 revenue as margins improve on product mix and efficiency gains
Filatex India Limited (NSE: FILATEX, BSE: 526227) reported stable revenue and improved profitability for the…
-
Man Industries (India) Limited reports strong Q3 FY26 earnings as margins expand and order book rises
Man Industries (India) Limited (NSE: MANINDS, BSE: 513269) reported a sharp increase in revenue, profit…